Corbus Pharmaceuticals price to sales ratio CRBP

Market value divided by revenue over the last twelve months, since 2016.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 68.0×; Nov 2022
10-year median: 86.2×
10-year range: 7.4× to 200×
Peer median: 1.4×

Corbus Pharmaceuticals' price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.

It was last meaningful in Nov 2022, at 68.0×.

On the days it had one over the last ten years, its median was 86.2×, from 7.4× in Mar 2020 to 200× in Dec 2016.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2022	68.0×	27.5×	183×
2021	50.1×	20.2×	96.6×
2020	17.9×	7.4×	105×
2019	9.9×	8.1×	177×
2018	116×	104×	173×
2017	138×	103×	199×
2016	198×	97.5×	200×

Against its peers

Companies in Drug Manufacturers - General nearest Corbus Pharmaceuticals' size, closest first, today.

Company	Price to sales ratio
CRBPCorbus Pharmaceuticals	n/m
LFVNLifevantage	0.4×
SPROSpero Therapeutics	1.4×
ATNMActinium Pharmaceuticals	n/m
NATRNatures Sunshine Products	0.4×
ARVNArvinas	1.5×
PBYIPuma Biotechnology	2.5×
IRWDIronwood Pharmaceuticals	1.5×
ZVRAZevra Therapeutics	4.3×
CRMDCorMedix	1.3×
COLLCollegium Pharmaceutical	0.9×
Peer median	1.4×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Corbus Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.